Company profile: Acorda Therapeutics
1.1 - Company Overview
Company description
- Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
Products and services
- AMPYRA: Dalfampridine oral medication engineered to improve walking in adults with multiple sclerosis, delivered as an oral formulation
- ARCUS Technology: Platform technology used for drug delivery, a drug-delivery platform that supports administering medicines
- INBRIJA: Levodopa inhalation powder for treating symptoms of Parkinson's disease, administered through an inhaled powder formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acorda Therapeutics
Leon Nanodrugs
HQ: Germany
Website
- Description: Provider of nanotechnology-based drug development, offering access to next-generation nano-formulated drugs, specialized product development of enhanced versions of existing products, and services enabling pre-clinical and clinical formulations for clients’ NCEs or branded drugs. Products include FR-JET System, NANOlab, NANOme, and NANOus for scalable, GMP-compliant nanocarrier manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leon Nanodrugs company profile →
Travanti Pharma
HQ: United States
Website
- Description: Provider of innovative drug delivery platforms that improve the safety, compliance, effectiveness, and ease of administration of medications delivered into the body; designs, develops, and markets these platforms to enhance medication delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Travanti Pharma company profile →
Biocorp Systems
HQ: France
Website
- Description: Provider of medical devices and drug delivery systems; a pharmaceutical company that develops, manufactures, and markets these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocorp Systems company profile →
Innocoll
HQ: United States
Website
- Description: Provider of targeted drug delivery solutions focused on biodegradable surgical implants and topically applied healthcare products, including XARACOLL, a resorbable collagen implant with bupivacaine for pain relief up to 24 hours after open inguinal hernia repair; POSIMIR, a single‑site bupivacaine injection providing relief up to 72 hours after arthroscopic subacromial decompression; the COLLARx collagen matrix platform; and CDMO services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innocoll company profile →
Stratagent Life Sciences
HQ: United States
Website
- Description: Provider of specialty drug therapies that are painless and non-invasive for various diseases, developing alternatives to injected treatments based on proprietary microjet technology to deliver large and small therapeutic molecules without a device penetrating into or through the skin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stratagent Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acorda Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acorda Therapeutics
2.2 - Growth funds investing in similar companies to Acorda Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acorda Therapeutics
4.2 - Public trading comparable groups for Acorda Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →